Genovis AB (publ.) (STO:GENO)

Market Cap	1.34B
Revenue (ttm)	146.00M
Net Income (ttm)	32.92M
Shares Out	65.47M
EPS (ttm)	0.50
PE Ratio	40.77
Forward PE	42.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,762
Average Volume	139,212
Open	21.00
Previous Close	21.00
Day's Range	20.30 - 21.00
52-Week Range	19.00 - 39.85
Beta	1.69
RSI	29.57
Earnings Date	Apr 28, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 146.00 million, a decrease of -8.22% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.